Sionna Therapeutics, Inc.

NasdaqGM:SION Stock Report

Market Cap: US$1.9b

Sionna Therapeutics Management

Management criteria checks 2/4

Sionna Therapeutics' CEO is Mike Cloonan, appointed in May 2021, has a tenure of 5.08 years. total yearly compensation is $6.98M, comprised of 9.3% salary and 90.7% bonuses, including company stock and options. directly owns 1.21% of the company’s shares, worth $23.41M. The average tenure of the management team and the board of directors is 4.4 years and 4 years respectively.

Key information

Mike Cloonan

Chief executive officer

US$7.0m

Total compensation

CEO salary percentage9.26%
CEO tenure5.1yrs
CEO ownership1.2%
Management average tenure4.4yrs
Board average tenure4yrs

Recent management updates

Recent updates

Analysis Article • Jun 21

Sionna Therapeutics (SION) Stock Looks Fairly Priced After A 157% One Year Run

Recent trading snapshot for Sionna Therapeutics stock Sionna Therapeutics (SION) has drawn attention after recent trading left the stock at a last close of $37.30, with returns mixed across different timeframes and a market value of about $1.68b. See our latest analysis for Sionna Therapeutics. Set against a very strong 1 year total shareholder return of about 157%, Sionna Therapeutics’ recent 30 day share price decline of around 9% and year to date share price slip of roughly 5% suggest some...
Seeking Alpha • Nov 07

Sionna Therapeutics Q3 2025: Advancing CF Pipeline Toward Proof-Of-Concept

Summary Sionna Therapeutics reported a narrowed GAAP EPS loss and maintains a strong $325M cash position, funding operations through 2028. SION advanced its cystic fibrosis pipeline, launching Phase 2a for SION-719 and Phase 1 for SION-451, with topline data expected mid-2026. The stock has surged 44% since the previous buy call, driven by pipeline momentum and investor confidence in its NBD1 stabiliser programs. Despite the recent pullback from $42 to $35, SION presents continued upside potential ahead of key clinical catalysts in 2026. Read the full article on Seeking Alpha
Analysis Article • Aug 24

Here's Why We're Not Too Worried About Sionna Therapeutics' (NASDAQ:SION) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

CEO Compensation Analysis

How has Mike Cloonan's remuneration changed compared to Sionna Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$86m

Dec 31 2025US$7mUS$647k

-US$75m

Sep 30 2025n/an/a

-US$71m

Jun 30 2025n/an/a

-US$76m

Mar 31 2025n/an/a

-US$66m

Dec 31 2024US$4mUS$506k

-US$62m

Sep 30 2024n/an/a

-US$58m

Dec 31 2023US$754kUS$487k

-US$47m

Compensation vs Market: Mike's total compensation ($USD6.98M) is above average for companies of similar size in the US market ($USD5.24M).

Compensation vs Earnings: Mike's compensation has increased whilst the company is unprofitable.

CEO

Mike Cloonan (54 yo)

5.1yrs
Tenure
US$6,981,217
Compensation

Mr. Michael Cloonan, also known as Mike, M.B.A. has been an Independent Director of bluebird bio, Inc. from June 20, 2024. He also serves as Advisor since February 2022 at RA Capital Management, L.P. He ha...

Leadership Team

NamePositionTenureCompensationOwnership
Michael Cloonan
President5.1yrsUS$6.98m1.21%
$ 23.4m
Elena Ridloff
Chief Financial Officer4.8yrsUS$2.86m0.085%
$ 1.6m
Caroline Beer
Chief Business Officerless than a yearUS$5.59mno data
Greg Hurlbut
Co-Founder & Senior VP of Discovery Research7.4yrsno datano data
Mark Munson
Co-founder & Senior VP of Medicinal Chemistry7.4yrsno datano data
Meghan Bagshaw
Vice President of Programsno datano datano data
Andy Chu
Vice President of Information & Technology4.4yrsno datano data
Jennifer Fitzpatrick
Chief Legal Officer2yrsno datano data
Sarah Spencer
Vice President of Corporate Communicationsless than a yearno datano data
Vanya Sagar
Chief People Officer3.6yrsno datano data
Charlotte McKee
Chief Medical Officer5yrsUS$1.28m0.063%
$ 1.2m
Mara Furlow
Senior Vice President of Global Regulatory Affairs & Quality3.2yrsno datano data
4.4yrs
Average Tenure
49.5yo
Average Age

Experienced Management: SION's management team is considered experienced (4.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Michael Cloonan
President5.1yrsUS$6.98m1.21%
$ 23.4m
John Lowe
Member of Scientific Advisory Board3.8yrsno datano data
Peter Thompson
Independent Director4.3yrsUS$279.89kno data
Taiyin Yang
Member of Scientific Advisory Board3.8yrsno datano data
Bruce Booth
Independent Director6yrsUS$281.24kno data
Joshua Resnick
Independent Director6.5yrsUS$275.84kno data
Paul Clancy
Independent Chairman4yrsUS$323.14k0%
$ 0
Lucian Iancovici
Independent Director6.5yrsno datano data
Mark Namchuk
Member of Scientific Advisory Board3.8yrsno datano data
Laurie Stelzer
Independent Director1.6yrsUS$299.64kno data
John Macor
Chair of Scientific Advisory Boardno datano datano data
Joanne Viney
Independent Director1.4yrsUS$810.32kno data
4.0yrs
Average Tenure
58yo
Average Age

Experienced Board: SION's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/26 23:26
End of Day Share Price 2026/06/26 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Sionna Therapeutics, Inc. is covered by 12 analysts. 10 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Kambiz YazdiBTIG
Jonathan WollebenCitizens JMP Securities, LLC
Ilya ZubkovFreedom Broker